Timing of Susceptibility to Mortality and Heart Failure in Patients With Preexisting Atrial Fibrillation After Transcatheter Aortic Valve Implantation

Hirofumi Hioki, Yusuke Watanabe, Ken Kozuma, Yugo Nara, Hideyuki Kawashima, Fukuko Nagura, Makoto Nakashima, Akihisa Kataoka, Masanori Yamamoto, Toru Naganuma, Motoharu Araki, Norio Tada, Shinichi Shirai, Futoshi Yamanaka, Kentaro Hayashida

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The relationship between cardiac rhythm and adverse events after transcatheter aortic valve implantation (TAVI) remains unclear. To compare the prognostic impact of preexisting atrial fibrillation (AF) and new-onset AF (NOAF) after TAVI, we assessed 1,124 patients (846 with sinus rhythm [SR], 49 with NOAF, and 229 with preexisting AF) who underwent TAVI with a balloon-expandable valve from October 2013 to April 2016. The incidences of all-cause death and rehospitalization for heart failure (HF) were retrospectively evaluated. The median follow-up period was 370 days (range 188 to 613). In the Kaplan-Meier analysis, the incidences of all-cause death and rehospitalization for HF were significantly higher in patients with preexisting AF than those in patients with NOAF and SR. The multivariable analysis showed that preexisting AF was significantly associated with increased all-cause death (hazard ratio [HR] 1.54; 95% confidence interval [CI] 1.02 to 2.34) and rehospitalization for HF (HR 2.94; 95% CI 1.75 to 4.93). The landmark analysis demonstrated that patients with preexisting AF had a significantly higher incidence of rehospitalization for HF within the first 6 months after TAVI (HR 4.04; 95% CI 2.23 to 7.32), and a higher incidence of all-cause death from 6 months to 2 years after TAVI (HR 2.12; 95% CI 1.15 to 3.90). Our study demonstrated that preexisting AF increased the risk of all-cause death and rehospitalization for HF after TAVI in comparison with NOAF or SR. Moreover, there was a specific timing of susceptibility to all-cause death and rehospitalization for HF after TAVI.

Original languageEnglish
JournalAmerican Journal of Cardiology
DOIs
Publication statusAccepted/In press - 2017

Fingerprint

Atrial Fibrillation
Heart Failure
Cause of Death
Mortality
Confidence Intervals
Incidence
Kaplan-Meier Estimate
Transcatheter Aortic Valve Replacement

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Timing of Susceptibility to Mortality and Heart Failure in Patients With Preexisting Atrial Fibrillation After Transcatheter Aortic Valve Implantation. / Hioki, Hirofumi; Watanabe, Yusuke; Kozuma, Ken; Nara, Yugo; Kawashima, Hideyuki; Nagura, Fukuko; Nakashima, Makoto; Kataoka, Akihisa; Yamamoto, Masanori; Naganuma, Toru; Araki, Motoharu; Tada, Norio; Shirai, Shinichi; Yamanaka, Futoshi; Hayashida, Kentaro.

In: American Journal of Cardiology, 2017.

Research output: Contribution to journalArticle

Hioki, H, Watanabe, Y, Kozuma, K, Nara, Y, Kawashima, H, Nagura, F, Nakashima, M, Kataoka, A, Yamamoto, M, Naganuma, T, Araki, M, Tada, N, Shirai, S, Yamanaka, F & Hayashida, K 2017, 'Timing of Susceptibility to Mortality and Heart Failure in Patients With Preexisting Atrial Fibrillation After Transcatheter Aortic Valve Implantation', American Journal of Cardiology. https://doi.org/10.1016/j.amjcard.2017.07.061
Hioki, Hirofumi ; Watanabe, Yusuke ; Kozuma, Ken ; Nara, Yugo ; Kawashima, Hideyuki ; Nagura, Fukuko ; Nakashima, Makoto ; Kataoka, Akihisa ; Yamamoto, Masanori ; Naganuma, Toru ; Araki, Motoharu ; Tada, Norio ; Shirai, Shinichi ; Yamanaka, Futoshi ; Hayashida, Kentaro. / Timing of Susceptibility to Mortality and Heart Failure in Patients With Preexisting Atrial Fibrillation After Transcatheter Aortic Valve Implantation. In: American Journal of Cardiology. 2017.
@article{42f44770709842a48522ff06b11b9b75,
title = "Timing of Susceptibility to Mortality and Heart Failure in Patients With Preexisting Atrial Fibrillation After Transcatheter Aortic Valve Implantation",
abstract = "The relationship between cardiac rhythm and adverse events after transcatheter aortic valve implantation (TAVI) remains unclear. To compare the prognostic impact of preexisting atrial fibrillation (AF) and new-onset AF (NOAF) after TAVI, we assessed 1,124 patients (846 with sinus rhythm [SR], 49 with NOAF, and 229 with preexisting AF) who underwent TAVI with a balloon-expandable valve from October 2013 to April 2016. The incidences of all-cause death and rehospitalization for heart failure (HF) were retrospectively evaluated. The median follow-up period was 370 days (range 188 to 613). In the Kaplan-Meier analysis, the incidences of all-cause death and rehospitalization for HF were significantly higher in patients with preexisting AF than those in patients with NOAF and SR. The multivariable analysis showed that preexisting AF was significantly associated with increased all-cause death (hazard ratio [HR] 1.54; 95{\%} confidence interval [CI] 1.02 to 2.34) and rehospitalization for HF (HR 2.94; 95{\%} CI 1.75 to 4.93). The landmark analysis demonstrated that patients with preexisting AF had a significantly higher incidence of rehospitalization for HF within the first 6 months after TAVI (HR 4.04; 95{\%} CI 2.23 to 7.32), and a higher incidence of all-cause death from 6 months to 2 years after TAVI (HR 2.12; 95{\%} CI 1.15 to 3.90). Our study demonstrated that preexisting AF increased the risk of all-cause death and rehospitalization for HF after TAVI in comparison with NOAF or SR. Moreover, there was a specific timing of susceptibility to all-cause death and rehospitalization for HF after TAVI.",
author = "Hirofumi Hioki and Yusuke Watanabe and Ken Kozuma and Yugo Nara and Hideyuki Kawashima and Fukuko Nagura and Makoto Nakashima and Akihisa Kataoka and Masanori Yamamoto and Toru Naganuma and Motoharu Araki and Norio Tada and Shinichi Shirai and Futoshi Yamanaka and Kentaro Hayashida",
year = "2017",
doi = "10.1016/j.amjcard.2017.07.061",
language = "English",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Timing of Susceptibility to Mortality and Heart Failure in Patients With Preexisting Atrial Fibrillation After Transcatheter Aortic Valve Implantation

AU - Hioki, Hirofumi

AU - Watanabe, Yusuke

AU - Kozuma, Ken

AU - Nara, Yugo

AU - Kawashima, Hideyuki

AU - Nagura, Fukuko

AU - Nakashima, Makoto

AU - Kataoka, Akihisa

AU - Yamamoto, Masanori

AU - Naganuma, Toru

AU - Araki, Motoharu

AU - Tada, Norio

AU - Shirai, Shinichi

AU - Yamanaka, Futoshi

AU - Hayashida, Kentaro

PY - 2017

Y1 - 2017

N2 - The relationship between cardiac rhythm and adverse events after transcatheter aortic valve implantation (TAVI) remains unclear. To compare the prognostic impact of preexisting atrial fibrillation (AF) and new-onset AF (NOAF) after TAVI, we assessed 1,124 patients (846 with sinus rhythm [SR], 49 with NOAF, and 229 with preexisting AF) who underwent TAVI with a balloon-expandable valve from October 2013 to April 2016. The incidences of all-cause death and rehospitalization for heart failure (HF) were retrospectively evaluated. The median follow-up period was 370 days (range 188 to 613). In the Kaplan-Meier analysis, the incidences of all-cause death and rehospitalization for HF were significantly higher in patients with preexisting AF than those in patients with NOAF and SR. The multivariable analysis showed that preexisting AF was significantly associated with increased all-cause death (hazard ratio [HR] 1.54; 95% confidence interval [CI] 1.02 to 2.34) and rehospitalization for HF (HR 2.94; 95% CI 1.75 to 4.93). The landmark analysis demonstrated that patients with preexisting AF had a significantly higher incidence of rehospitalization for HF within the first 6 months after TAVI (HR 4.04; 95% CI 2.23 to 7.32), and a higher incidence of all-cause death from 6 months to 2 years after TAVI (HR 2.12; 95% CI 1.15 to 3.90). Our study demonstrated that preexisting AF increased the risk of all-cause death and rehospitalization for HF after TAVI in comparison with NOAF or SR. Moreover, there was a specific timing of susceptibility to all-cause death and rehospitalization for HF after TAVI.

AB - The relationship between cardiac rhythm and adverse events after transcatheter aortic valve implantation (TAVI) remains unclear. To compare the prognostic impact of preexisting atrial fibrillation (AF) and new-onset AF (NOAF) after TAVI, we assessed 1,124 patients (846 with sinus rhythm [SR], 49 with NOAF, and 229 with preexisting AF) who underwent TAVI with a balloon-expandable valve from October 2013 to April 2016. The incidences of all-cause death and rehospitalization for heart failure (HF) were retrospectively evaluated. The median follow-up period was 370 days (range 188 to 613). In the Kaplan-Meier analysis, the incidences of all-cause death and rehospitalization for HF were significantly higher in patients with preexisting AF than those in patients with NOAF and SR. The multivariable analysis showed that preexisting AF was significantly associated with increased all-cause death (hazard ratio [HR] 1.54; 95% confidence interval [CI] 1.02 to 2.34) and rehospitalization for HF (HR 2.94; 95% CI 1.75 to 4.93). The landmark analysis demonstrated that patients with preexisting AF had a significantly higher incidence of rehospitalization for HF within the first 6 months after TAVI (HR 4.04; 95% CI 2.23 to 7.32), and a higher incidence of all-cause death from 6 months to 2 years after TAVI (HR 2.12; 95% CI 1.15 to 3.90). Our study demonstrated that preexisting AF increased the risk of all-cause death and rehospitalization for HF after TAVI in comparison with NOAF or SR. Moreover, there was a specific timing of susceptibility to all-cause death and rehospitalization for HF after TAVI.

UR - http://www.scopus.com/inward/record.url?scp=85028041070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028041070&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2017.07.061

DO - 10.1016/j.amjcard.2017.07.061

M3 - Article

C2 - 28842144

AN - SCOPUS:85028041070

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

ER -